US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:19:57 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
Next:French sports minister calls for sanctions after Monaco player tapes over anti
You may also like
- Kid Rock 'uses N
- Xi sends congratulatory message to 37th AU Summit
- China committed to promoting peace talks on Ukraine issue: top diplomat
- 50 city volunteer service stations for the Chengdu 2021 FISU Games went live
- MPs' fury at 'virtue
- Xiplomacy: China, Nauru Gathering Momentum for Growth of Ties
- Protection efforts lift crested ibis population
- Forum calls for end to anti
- Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse